Cannabinoids

GW Pharma Sells for Billions; Psychedelic Company Following Similar Path

Retrieved on: 
Tuesday, June 29, 2021
Drugs, Health sciences, Health care, Herbalism, Medicinal plants, Cannabinoids, Natural phenols, Resorcinols, Cannabidiol, Jazz Pharmaceuticals, Medical cannabis, Legality of cannabis

Jazz Pharmaceuticals paying $7.2 billion for cannabis drug maker GW Pharma has investors looking at early-stage psychedelic companies.

Key Points: 
  • Jazz Pharmaceuticals paying $7.2 billion for cannabis drug maker GW Pharma has investors looking at early-stage psychedelic companies.
  • Tryp Therapeutics is one of only a handful of companies moving into Phase 2 clinical trials with a psychedelic compound.
  • GW was a true trendsetter with its Epidiolex (cannabidiol) for controlling seizures in rare forms of epilepsy.
  • A similar trend is underway with psychedelics, which are already benefiting from the path carved by cannabis drug development pioneers such as GW.

InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

Retrieved on: 
Tuesday, June 29, 2021
Cannabinoids, Natural phenols, Pharmaceuticals policy, Health care, Health, INMED, Cannabinol, Pharmaceutical industry in China

The closing of the private placement is expected to occur on or about July 2, 2021, subject to satisfaction of customary closing conditions.

Key Points: 
  • The closing of the private placement is expected to occur on or about July 2, 2021, subject to satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years.
  • About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (CBN), and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids.

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

Retrieved on: 
Tuesday, June 29, 2021
Cannabinoids, INMED, Cannabichromene, CBC, Wellness

BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector.

Key Points: 
  • BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector.
  • In addition to their manufacturing and commercial activities in the health and wellness arena, BayMedica is researching cannabinoid analogs as potential drug candidates for pharmaceutical purposes.
  • In November 2020, InMed and BayMedica entered into a reciprocal Research Collaboration Agreement to explore synergies between their respective technologies.
  • Further particulars of the proposed transaction will be provided upon InMed and BayMedica entering into a definitive agreement for the transaction.

Global Cannabidiol Market (2021 to 2026) - by Source, Distribution Channel, Product, Route of Administration, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Alternative medicine, Health, Retail, Tobacco, Pharmaceutical, Drugs, Cannabinoids, Analgesics, Anticonvulsants, Cannabidiol, Resorcinols, CBD

Changing regulatory landscape and legalization for approval of CBD-based products globally is also expected to propel the market growth.

Key Points: 
  • Changing regulatory landscape and legalization for approval of CBD-based products globally is also expected to propel the market growth.
  • However, the factor such as the high cost of CBD and barriers in its marketing hinders the market growth.
  • The absence of legalization programs in several Asian and African countries is also impeding the growth of the CBD market.
  • The Global Cannabidiol Market is segmented further based on Source, Distribution Channel, Product, Route of Administration, End-User, and Geography.

CBDfx Launches CBD-Infused Pet Balm As Pet CBD Industry Continues to Skyrocket

Retrieved on: 
Wednesday, June 23, 2021
Drugs, Articles, Philosophical theories, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Veganism

LOS ANGELES, June 23, 2021 /PRNewswire/ -- CBD industry giant, CBDfx , continues to broaden its wildly popular CBD pet line, announcing today the addition of a new all-natural Calming & Moisturizing CBD Pet Balm targeting problem areas, such as paw pads and noses, to provide quick, concentrated relief and a boost of calm for pets.

Key Points: 
  • LOS ANGELES, June 23, 2021 /PRNewswire/ -- CBD industry giant, CBDfx , continues to broaden its wildly popular CBD pet line, announcing today the addition of a new all-natural Calming & Moisturizing CBD Pet Balm targeting problem areas, such as paw pads and noses, to provide quick, concentrated relief and a boost of calm for pets.
  • CBDfx's all-natural Calming & Moisturizing CBD Pet Balm provides quick, concentrated relief and a boost of calm for pets
    Consumers spent $426 million on Pet CBD in 2020 and are expected to reach $629 million in sales by the end of 2021, according to industry researcher, Brightfield Group, whose reports show that Pet CBD is more than a passing fad.
  • The Calming & Moisturizing CBD Pet Balm joins CBDfx's vegan Pet Treats in two variations targeting anxiety and joint health, and their full line of vegan CBD Oil for Pets.
  • Founded in 2014 with a mission to push quality to the forefront of the CBD industry, CBDfx continues to provide some of the finest, purest, and most effective CBD products in the world.

CBDistillery™ Sets Aside Thousands Of Products To Advance The Efficacy of Hemp-Derived Wellness Products

Retrieved on: 
Thursday, June 17, 2021
Drugs, Psychoactive drugs, Entheogens, Euphoriants, Anticonvulsants, Cannabidiol, Cannabinoids, Hemp, Cannabis

CBDistillery is on a mission to be the premier educational resource and "one-stop-shop" for consumers curious about hemp-derived CBD, CBG, and CBN products.

Key Points: 
  • CBDistillery is on a mission to be the premier educational resource and "one-stop-shop" for consumers curious about hemp-derived CBD, CBG, and CBN products.
  • Eligible participants will receive two complimentary CBDistillery products - a 1000mg Isolate CBD Oil, and a 1000mg Broad Spectrum CBD Oil.
  • "At Balanced Health Botanicals, we're invested in bringing efficacy to hemp-derived wellness products through dynamic research-based partnerships.
  • CBDistillery was founded in 2016 with the belief that everyone deserves access to high quality, effective, and affordable CBD products.

Leading CBD and Wellness Brands Launch in the Caribbean and Central America

Retrieved on: 
Wednesday, June 16, 2021
Drugs, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, The WB, CBD

WB Canna Co. & Wellness is a wholly owned subsidiary of WEBB Banks, the leading premium wine and spirits distributor in the Caribbean and Central America, and travel retail in the Americas.

Key Points: 
  • WB Canna Co. & Wellness is a wholly owned subsidiary of WEBB Banks, the leading premium wine and spirits distributor in the Caribbean and Central America, and travel retail in the Americas.
  • "Looking at the rapid growth of CBD and wellness brands, I've never before seen that level of consumer enthusiasm for new brands and categories.
  • Its broader wellness portfolio, which excludes CBD products, will launch in all Caribbean, Central American, and duty free markets.
  • WB Canna Co. & Wellness, a wholly owned subsidiary ofMiami-based WEBB Banks, distributes top-quality cannabidiol (CBD) and wellness products in the Caribbean, Central America, and Travel Retail.

CBD Global Issues Third Bi-Weekly Status Report Regarding Management Cease Trade Order

Retrieved on: 
Tuesday, June 15, 2021
Drugs, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, CBD, Cannabis, Hemp

As previously announced in the Corporations press releases, the Corporation applied for and was granted a management cease trade order in respect of the delayed Annual Filings (the MCTO) by theAlberta Securities Commission.

Key Points: 
  • As previously announced in the Corporations press releases, the Corporation applied for and was granted a management cease trade order in respect of the delayed Annual Filings (the MCTO) by theAlberta Securities Commission.
  • The MCTO does not affect the ability of the general investing public to trade in the Corporations listed common shares.
  • ABOUT CBD GLOBAL SCIENCES INC.
    CBD Global Sciences Inc., is a vertically integrated hemp-based CBD producer, extractor, and branding investment vehicle which currently owns two product categories, branded under the name AETHICS ( www.aethics.com ) and CANNAOIL ( www.cannaoilshop.com ), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals and CBD hydration products.
  • CBD Globals hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

New Leafreport Research Reveals More Than Half of Hemp-Derived Products Tested Had Illegal Levels of Delta-9 THC

Retrieved on: 
Monday, June 14, 2021
Drugs, Psychoactive drugs, Euphoriants, Appetite stimulants, Entheogens, Cannabinoids, Cannabis, Tetrahydrocannabinol, Hemp, Drugwipe test, Cannabidiol

Among the research findings, it was found that more than half of the products tested had illegal levels of Delta-9 THC.

Key Points: 
  • Among the research findings, it was found that more than half of the products tested had illegal levels of Delta-9 THC.
  • In addition, out of 38 tested products, only 12 (32%) had the advertised amount of Delta-8 THC.
  • Among the findings, the Company found that 20 (53%) of the products were over the hemp legal limit for Delta-9 THC (0.3%), containing as much as 15.2% THC.
  • This is why we felt it was important to test these products, said Lital Shafir, the head of product at Leafreport.

Advancing Medical R&D for Cannabinoid Medicinal Uses Identifying Growing Number of Health Benefits

Retrieved on: 
Thursday, June 10, 2021
Drugs, Organ systems, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Anxiety, Health care, Forward-looking statement, Neuroprotection

But there's growing awareness about the possible health benefits of CBD oil.

Key Points: 
  • But there's growing awareness about the possible health benefits of CBD oil.
  • An article in Healthline.com published what you need to know about several potential medical uses of CBD and where the research stands.
  • It highlighted Anxiety Relief, Anti-seizure, Neuroprotective, Pain relief and Cancer.CBD may be able to help manage anxiety.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.